Evidence map›Paper›PMID 28499402›Full record

ArticleStem cell research & therapy2017

ERK signaling is required for VEGF-A/VEGFR2-induced differentiation of porcine adipose-derived mesenchymal stem cells into endothelial cells.

Sami G Almalki, Devendra K Agrawal

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sami G AlmalkiDepartment of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, 68178, USA.
Devendra K AgrawalDepartment of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, 68178, USA. dkagr@creighton.edu.
Creighton University · US

Funding

MESENCHYMAL STEM CELLS IN THE PREVENTION OF THROMBOSIS AND NEOINTIMAL HYPERPLASIAR01HL112597 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2012 to 2016
$3.8M
EPICARDIAL ADIPOSE TISSUE, OBESITY AND INFLAMMATION IN ATHEROSCLEROSISR01HL120659 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2013 to 2017
$3.6M
VITAMIN D AND IMMUNOMODULATION IN CORONARY ARTERY DISEASER01HL116042 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2012 to 2016
$3.3M
NHLBI NIH HHS R01 HL112597NHLBI NIH HHS R01 HL116042NHLBI NIH HHS R01 HL120659
6 · The paper itself

Abstract

backgroundCell-based therapy that can rejuvenate the endothelium with stimulated adipose-derived mesenchymal stem cells (AMSCs) is a promising therapeutic strategy for the re-endothelialization of denuded arteries at the stenting site. Previously, we have shown that silencing of MMP-2 and MMP-14 inhibits vascular endothelial growth factor receptor type 2 (VEGFR2) cleavage, and induces differentiation of AMSCs toward the endothelial cell (EC) lineage. In this study, we examined the underlying signaling pathways that regulate differentiation of AMSCs to ECs in vitro through VEGFR2.

methodsAMSCs were isolated from porcine abdominal adipose tissue. The isolated AMSCs were characterized by positive expression of CD29, CD44, and CD90 and negative expression of CD11b and CD45. The isolated MSCs were transfected with siRNA to silence MMP-2, MMP-14, and angiotensin receptor 2 (ATR2). Cells were suspended either in endothelial basal media (EBM) or endothelial growth media (EGM) with various treatments. Flow cytometry was performed to examine the expression of EC markers, and western blot analysis was performed to examine the expression and activity of various kinases. Scratch assay was performed to examine the cell migration. Data were analyzed by ANOVA using PRISM GraphPad.

resultsAfter 10 days of stimulation for EC differentiation, the morphology of AMSCs changed to a morphology similar to that of ECs. Silencing MMP-2 and MMP-14 resulted in significant decrease in the number of migrated cells compared with the EGM-only group. ATR2 siRNA transfection did not affect the migration and differentiation of AMSCs to ECs. Stimulation of AMSCs for EC differentiation with or without MMP-2 or MMP-14 siRNA resulted in significant increase in p-ERK, and significant decrease in p-JNK. There was no significant change in p-p38 in all three groups compared with the EBM group. ERK inhibition resulted in significant decrease in the expression of EC markers in the EGM, EGM + MMP-2 siRNA, and EGM + MMP-14 siRNA groups. The VEGFR2 kinase inhibitor induced a dose-dependent inhibition of ERK.

conclusionThe ERK signaling pathway is critical for VEGF-A/VEGFR2-induced differentiation of AMSCs into ECs. These findings provide new insights into the role of the ERK signaling pathway in AMSC differentiation to ECs for potential clinical use in cardiovascular diseases.

Indexed as

Adipose TissueAnimalsBiomarkersCell DifferentiationCell MovementEndothelial CellsExtracellular Signal-Regulated MAP KinasesImmunophenotypingMAP Kinase Signaling SystemMesenchymal Stem CellsModels, BiologicalPhosphorylationProtein Kinase InhibitorsReceptor, Angiotensin, Type 2RNA, Small InterferingSus scrofaBiomarkersExtracellular Signal-Regulated MAP KinasesProtein Kinase InhibitorsReceptor, Angiotensin, Type 2RNA, Small InterferingVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Adipose-derived mesenchymal stem cellsAngiotensin type-2 receptorc-Jun NH2-terminal kinaseEndothelial cell differentiationExtracellular signal-regulated kinase 1/2Mitogen-activated protein kinaseStress activated protein kinase-2Vascular endothelial growth factor receptor type 2

Identifiers

PMID28499402
PMCPMC5429549
OpenAlexW2612784079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.